Does attainment of target levels of growth hormone and insulin-like growth factor I improve acromegaly prognosis?

Nature Clinical Practice Endocrinology and Metabolism

Volumn 5, Issue 2, 2009, Pages 70-71

  Chanson, Philippe ^a,b   Maison, Patrick ^c,d  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^d HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; CARDIOMYOPATHY; COMORBIDITY; DISEASE CONTROL; GROWTH HORMONE BLOOD LEVEL; HUMAN; MORTALITY; NOTE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; SLEEP APNEA SYNDROME;

EID: 58849095752     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet1048     Document Type: Note

References (7)

1. Giustina A et al. (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85: 526-529
2. Holdaway IM et al. (2008) A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159: 89-95
3. Kauppinen-Makelin R et al. (2005) A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 90: 4081-4086
4. Colao A et al. (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25: 102-152
5. Nachtigall L et al. (2008) Changing patterns in diagnosis and therapy of acromegaly over two decades. J Clin Endocrinol Metab 93: 2035-2041
6. Maison P and Chanson P (2006) Less is more risky? Growth hormone and insulin-like growth factor I levels and cardiovascular risk. Nat Clin Pract Endocrinol Metab 2: 650-651
7. Cazabat L et al. (2008) Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly. Pituitary 11: 129-139